These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 10355058)

  • 1. [Treatment of rheumatoid arthritis with cytokine antagonists].
    Manger B
    Z Arztl Fortbild Qualitatssich; 1999 Mar; 93(2):101-4. PubMed ID: 10355058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Blockade of TNFalpha--new therapeutic principle in severe rheumatoid arthritis].
    Larsson P; Bratt J; Harju A; van Vollenhoven R; Klareskog L
    Lakartidningen; 2001 Feb; 98(8):828-31. PubMed ID: 11265568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockade.
    Redlich K; Schett G; Steiner G; Hayer S; Wagner EF; Smolen JS
    Arthritis Rheum; 2003 Dec; 48(12):3308-19. PubMed ID: 14673982
    [No Abstract]   [Full Text] [Related]  

  • 4. [New biological therapeutic options for the treatment of RE: inhibition of costimulatory molecules and blockade of Interleukin-6-interaction].
    Perniok A; Rubbert-Roth A
    Z Rheumatol; 2003 Oct; 62(5):433-8. PubMed ID: 14579030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis.
    Cohen SB
    Rheum Dis Clin North Am; 2004 May; 30(2):365-80, vii. PubMed ID: 15172046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis.
    Charles P; Elliott MJ; Davis D; Potter A; Kalden JR; Antoni C; Breedveld FC; Smolen JS; Eberl G; deWoody K; Feldmann M; Maini RN
    J Immunol; 1999 Aug; 163(3):1521-8. PubMed ID: 10415055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evidence-based treatment of methotrexate-resistant rheumatoid arthritis. Cytokine antagonists].
    Schnabel A; Gross WL
    Dtsch Med Wochenschr; 2003 Jan; 128(5):201-3. PubMed ID: 12557112
    [No Abstract]   [Full Text] [Related]  

  • 8. Developing a new generation of TNFalpha antagonists for the treatment of rheumatoid arthritis.
    Fleischmann R; Shealy D
    Mol Interv; 2003 Sep; 3(6):310-8. PubMed ID: 14993463
    [No Abstract]   [Full Text] [Related]  

  • 9. [Redefining treatment of rheumatic arthritis with anti-cytokines].
    Gabay C; So A
    Rev Med Suisse; 2007 Mar; 3(103):715-7. PubMed ID: 17458148
    [No Abstract]   [Full Text] [Related]  

  • 10. Tumor necrosis factor inhibitors for rheumatoid arthritis.
    Jones RE; Moreland LW
    Bull Rheum Dis; 1999; 48(3):1-4. PubMed ID: 10408141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Tumor necrosis factor modulators in the treatment of rheumatoid arthritis].
    Konttinen YT; Valleala H; Honkanen V; Törnwall J; Tensing EK; Sorsa T; Nordström D
    Duodecim; 1999; 115(18):1969-76. PubMed ID: 11941814
    [No Abstract]   [Full Text] [Related]  

  • 12. Future trends in the treatment of rheumatoid arthritis: cytokine targets.
    Breedveld FC
    Rheumatology (Oxford); 1999 Nov; 38 Suppl 2():11-3. PubMed ID: 10646483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Role of TNF-alpha and cytokines in the physiopathology of rheumatoid arthritis. Therapeutic perspectives].
    Meyer O
    Bull Acad Natl Med; 2003; 187(5):935-54; discussion 954-5. PubMed ID: 14979058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cytokines and their antagonists in the treatment of rheumatoid arthritis].
    Klimiuk PA; Sierakowski S
    Przegl Lek; 2002; 59(2):108-12. PubMed ID: 12152246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenesis of rheumatoid arthritis: targeting cytokines.
    Zwerina J; Redlich K; Schett G; Smolen JS
    Ann N Y Acad Sci; 2005 Jun; 1051():716-29. PubMed ID: 16127012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Melanoma inhibitory activity, a biomarker related to chondrocyte anabolism, is reversibly suppressed by proinflammatory cytokines in rheumatoid arthritis.
    Vandooren B; Cantaert T; van Lierop MJ; Bos E; De Rycke L; Veys EM; De Keyser F; Bresnihan B; Luyten FP; Verdonk PC; Tak PP; Boots AH; Baeten D
    Ann Rheum Dis; 2009 Jun; 68(6):1044-50. PubMed ID: 18633128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
    Zwerina J; Hayer S; Tohidast-Akrad M; Bergmeister H; Redlich K; Feige U; Dunstan C; Kollias G; Steiner G; Smolen J; Schett G
    Arthritis Rheum; 2004 Jan; 50(1):277-90. PubMed ID: 14730626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokine inhibitors in rheumatoid arthritis and other autoimmune diseases.
    Williams RO; Paleolog E; Feldmann M
    Curr Opin Pharmacol; 2007 Aug; 7(4):412-7. PubMed ID: 17627887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New drug treatments for rheumatoid arthritis].
    Nordström DC; Konttinen YT
    Duodecim; 2000; 116(11):1221-5. PubMed ID: 11989008
    [No Abstract]   [Full Text] [Related]  

  • 20. Emerging biologic drugs for the treatment of rheumatoid arthritis.
    Puppo F; Murdaca G; Ghio M; Indiveri F
    Autoimmun Rev; 2005 Nov; 4(8):537-41. PubMed ID: 16214092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.